WO2005121181A1 - Polyethyleneglycol-oligopeptides de type branchement d'arbre multipoint et leurs derives actifs et composes - Google Patents
Polyethyleneglycol-oligopeptides de type branchement d'arbre multipoint et leurs derives actifs et composes Download PDFInfo
- Publication number
- WO2005121181A1 WO2005121181A1 PCT/CN2005/000834 CN2005000834W WO2005121181A1 WO 2005121181 A1 WO2005121181 A1 WO 2005121181A1 CN 2005000834 W CN2005000834 W CN 2005000834W WO 2005121181 A1 WO2005121181 A1 WO 2005121181A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polyethylene glycol
- group
- branched polyethylene
- amino acid
- dipeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Definitions
- the present invention relates to a novel multi-branched branched polyethylene glycol-amino acid oligopeptide, an active derivative thereof, and A conjugate of a drug molecule, a pharmaceutical composition containing the conjugate, a method for preparing the same, and their biomedical use, especially the use in the preparation of a medicament.
- BACKGROUND OF THE INVENTION Proteins, peptides, terpenes, steroids, alkaloids, flavones, anthraquinones, phenylpropanoids, etc. in natural pharmaceutical active ingredients have shown various effective properties in physiological activity and have been obtained in medicine. Wide application. Their glycosides, nucleosides, and peptide derivatives also have considerable applications.
- the bond of ⁇ -interferon and polyethylene glycol shows a longer circulating half-life and better therapeutic effect.
- Paclitaxel and polyethylene glycol linkages have correspondingly reduced toxicity and prolonged biological activity.
- the metabolic process of polyethylene glycol in the human body is quite clear, and it is a safe, no side effect drug modifier.
- a process called PEGylation is commonly used, that is, the end groups of polyethylene glycol are chemically activated to have an appropriate functional group. This functional group is related to the drug in the drug to be bound. At least one functional group is reactive and can form a stable bond with it.
- polyethylene glycol can be used to connect with many drugs.
- an object of the present invention is to provide a new type of polyethylene glycol compound capable of carrying more drugs, and a combination of the polyethylene glycol compound and a drug molecule.
- Another object of the present invention is to provide an application of the novel polyethylene glycol compound in preparing a gel.
- the novel polyethylene glycol compound provided by the present invention is a multi-branched branched polyethylene glycol compound, which contains more than two end groups. Compared with the existing linear PEG, it can be loaded with more drug molecules after modification. Based on such multi-branched branched polyethylene glycols, the present invention provides a novel multi-branched branched polyethylene glycol-amino acid oligopeptide and its active derivative, which will be able to significantly increase the loading rate of drug molecules.
- This multi-branch branched polyethylene glycol-amino acid oligopeptide active derivative can also form a gel under appropriate conditions.
- SUMMARY OF THE INVENTION One aspect of the present invention is to provide a multi-branched branched polyethylene glycol-amino acid oligopeptide of the general formula I and an active derivative compound thereof:
- N is an integer from 3 to 2000
- n is an integer from 2-12;
- i is an integer in 3_30;
- R 2 is a side chain group of an amino acid, and may be the same or different;
- X is a linking group selected from, but not limited to: 0 (CH 2 ) k CO, 0 (CH 2 ) kOCO, 0 (CH 2 ) k NHCO, NR (CH 2 ) k OCO, NR (CH 2 ) k HCO, N (CH 2 ) k CO, and k is an integer from 0 to 10;
- Y is selected from the group consisting of a hydroxyl group, an ester group, an acid chloride, a hydrazide, a maleimide, and a pyridine disulfide active group.
- the present invention provides a polyethylene glycol-amino acid oligopeptide of the general formula II:
- Ri is a central molecule that contains multiple end-group reactive groups. Linear polyethylene glycols derived from these groups eventually form multi-branched polyethylene glycols. Ri can be polyhydroxy molecules, polyamino molecules, poly Carboxyl molecule; n is any integer, characterizing its degree of polymerization, selected from 3 to 2000;
- n is an integer from 2-12;
- i is an integer from 3 to 30, which represents the number of forks;
- R 2 is a side chain group of related amino acids, and may be the same or different;
- X is a linking group, connecting the end group of the multi-branched branched polyethylene glycol with the amino group of the amino acid oligopeptide, selected from, but not limited to: 0 (CH 2 ) k CO, 0 (C3 ⁇ 4) k OCO, 0 (CH 2 ) k NHCO, NR (CH 2 ) k OCO, NR (CH 2 ) k NHCO, NR (CH 2 ) k CO, k is an integer from 0-10.
- 'More preferably, a compound of general formula Ila and general formula lib is provided:
- (lib) is a central molecule that contains multiple end-group reactive groups.
- Linear polyethylene glycols derived from these groups eventually form multi-branched polyethylene glycols, which can be polyhydroxy molecules, polyamino molecules, Polycarboxyl molecule n is any integer representing the degree of polymerization, and is selected from 3 to 2000;
- n is an integer from 2-12;
- j is an integer from 1 to 4;.
- i is an integer from 3 to 30, which represents the number of forks;
- R is selected from the group the group: H, C 12 Bu alkyl, substituted aryl, arylalkyl, heteroalkyl, substituted and
- X is a linking group, connecting the end group of the multi-branched branched polyethylene glycol with the amino group of the amino acid oligopeptide, selected from, but not limited to: 0 (C3 ⁇ 4) k CO, 0 (C3 ⁇ 4) k OCO, 0 (C3 ⁇ 4) k NHCO, NR (CH 2 ) k OCO, NR (CH 2 ) k NHCO NR (CH 2 ) k CO, k is an integer from 0-10.
- the amino acids are natural amino acids and synthetic amino acids, preferably glutamic acid, glycine, lysine, cystine, aspartic acid, arginine, tyrosine or Serine.
- the central molecule is pentaerythritol or glycerol.
- the multi-branched polyethylene glycol derived from pentaerythritol is a tetra-branched polyethylene glycol
- the multi-branched polyethylene glycol derived from glycerol is a tri-branch polyethylene glycol.
- the present invention provides a multi-branched branched polyethylene glycol-amino acid oligopeptide active derivative of the general formula III:
- linear polyethylene glycols derived from these Chinese groups eventually form multi-branched polyethylene glycols, which can be polyhydroxy molecules, polyamino molecules, polycarboxyl molecules;
- n is any integer, which characterizes its degree of polymerization, and is selected from 3 to 2000;
- n is an integer from 2-12;
- i is an integer from 3 to 30, which represents the number of forks;
- X is a linking group, which connects the end group of the multi-branched branched polyethylene glycol and the amino group of the amino acid oligopeptide, and is selected from but not limited to: 0 (CH 2 ) k CO, 0 (CH 2 ) k OCO, 0 ( CH 2 ) k NHCO, NR (CH 2 ) k OCO, NR (CH 2 ) k NHCO, NR (CH 2 ) k CO, k is an integer from 0 to 10;
- the z is an active group selected from, but not limited to, an ester group, a carbonate group, an acid chloride, a hydrazide, a maleimide, and a pyridine disulfide.
- the amino acids are natural amino acids and synthetic amino acids, preferably glutamic acid, Glycine, lysine, cystine, aspartic acid, arginine, tyrosine or serine.
- the Ri is pentaerythritol or glycerol.
- the multi-branched polyethylene glycol derived from pentaerythritol is a tetra-branched polyethylene glycol
- the multi-branched polyethylene glycol derived from glycerol is a tri-branch polyethylene glycol.
- Another aspect of the present invention is to provide a multi-branched branched polyethylene glycol-amino acid oligopeptide of the general formula IV and a combination of an active derivative thereof and a drug molecule-
- P is the above-mentioned multi-branched polyethylene glycol-amino acid oligopeptide or an active derivative thereof;
- ii is an integer from 1 to 30;
- TA is a drug molecule
- TA and P are linked through an easily hydrolyzable bond or a stable bond.
- the amino acid side chain group 3 ⁇ 4 can also participate in the connection of the drug molecule TA.
- the drug molecule is selected from the group consisting of amino acids, proteins, enzymes, nucleosides, sugars, organic acids, glycosides, flavonoids, quinones, terpenes, phenylpropanoids, steroids and their glycosides, biological
- the group consisting of bases is, alternatively, selected from the group consisting of Chinese toxin group, glycyrrhetic acid, boxwood, scutellarin, and scorolactone.
- the drug molecule is selected from the group consisting of paclitaxel (including docetaxel and deacetylpaclitaxel), camptothecin (including irinotecan and topotecan), etoposide, cantharidin, triptolide and their Derivatives consisting of a group of antitumor agents.
- paclitaxel including docetaxel and deacetylpaclitaxel
- camptothecin including irinotecan and topotecan
- etoposide cantharidin
- triptolide triptolide
- Yet another aspect of the present invention is to provide a pharmaceutical composition comprising the above-mentioned conjugate and a pharmaceutically acceptable carrier or excipient.
- the pharmaceutical composition is a tablet, a suppository, a pill, a soft and hard gelatin capsule. Dosage, powder, solution, suspension or aerosol formulation.
- the combination according to the present invention can improve drug absorption, prolong the action time, enhance the curative effect, reduce the dosage and avoid certain toxic and side effects.
- Another aspect of the present invention is to provide a polyethylene glycol-amino acid oligopeptide derived from the above-mentioned multi-branched branch and its derivative and a compound of the general formula V-(Z ⁇ (V) The gel formed,
- Z ⁇ is an active group that can react with the group Y to form a covalent or non-covalent bond
- R 3 is a class of molecules containing multiple (2-20) Z ⁇ active groups; R 3 can be a polymer or a small molecule ⁇ where the gel formed by covalent bonding can be characterized by:
- the product gel is preferably selected from the group consisting of polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polypropylene morpholine, polyamino acids, their copolymers, and their derivatives; more preferably, the selected From polylysine or polyglutamic acid, further, R 3 is selected from lysine oligopeptide or cystine oligopeptide.
- Another aspect of the present invention is to provide the use of the gel in biomedicine, including a surgical blocking agent, a surgical sealing material or a drug carrier comprising the gel.
- the gel of the present invention can be used as a drug carrier to improve drug absorption, prolong the action time, enhance the curative effect, reduce the dosage and avoid certain toxic and side effects.
- DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Polyethylene glycol (PEG) has the general structure as follows:
- R is H or —12 alkyl
- n is any integer indicating the degree of aggregation.
- R may be any lower fluorenyl group containing 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, n-pentyl Or n-hexyl.
- R is cycloalkyl
- R preferably contains 3 A 7-carbon cycloalkyl group, such as cyclopropyl, cyclobutyl, and cyclohexyl.
- a preferred cycloalkyl is cyclohexyl. Its typical compound is methoxy polyethylene glycol (mPEG).
- polyethylene glycol analogs or polyethylene glycol copolymers can also be used for this invention application, such as polypropylene glycol, polyvinyl alcohol, polypropylene morpholine, and the like.
- molecular weight is generally used, as long as the molecular weight of the polyethylene glycol forming the conjugate is 300 to 60,000 Daltons, which is equivalent to n of about 6 to 1,300. More preferably, n is 28, 112, and 450, which correspond to molecular weights of 1,325, 5000, and 20,000, respectively. Since the onset is usually defined by its average molecular weight rather than by self repeating units?
- n is any integer, which characterizes its degree of polymerization
- i represents The number of forks is an integer from 3 to 30.
- Ri may be a polyhydroxy molecule, which is connected with linear polyethylene glycol through ether bond and ester bond.
- said is polyhydroxypentaerythritol or glycerol.
- the multi-branched polyethylene glycol derived from pentaerythritol is a tetra-branched polyethylene glycol connected by an ether bond
- the poly-branched polyethylene glycol derived from glycerol is a tri-branched polyethylene glycol.
- Ri can also be a polyamino molecule, which is linked to linear polyethylene glycol via ammonia and amide bonds.
- R may also be a polycarboxyl molecule, which is connected to linear polyethylene glycol via an ester bond or an amide bond.
- the multi-branched polyethylene glycol-amino acid oligopeptide used in the conjugate of the present invention binds an amino acid oligopeptide, especially a glutamic acid oligopeptide, to the parent of the polymer, so that the polymer can be provided with a drug
- the connection point of the molecule is thus connected with free amino groups, hydroxyl groups, etc. in proteins, peptides or other natural pharmaceutical active ingredients.
- oligopeptides Especially for small molecule natural pharmaceutical active ingredients, more drug molecules can be linked in a multi-branch branched polyethylene glycol-glutamic acid oligopeptide to ensure a higher drug loading rate.
- glutamic acid oligopeptides have a defined number of active carboxyl groups in each oligopeptide chain. Therefore, when a drug such as a paclitaxel molecule is bound, the load factor of the drug molecule will be easily confirmed and repeated.
- An advantage of the present invention is that in addition to retaining the usual solubility, non-immunogenicity, and non-toxic characteristics of hydrophilic polyethylene glycol or its derivatives, oligopeptide groups will provide a loading point for drug molecules.
- the structure of amino acid oligopeptide is as follows:
- RI 2 m where-m is an integer from 2 to 12, which indicates the degree of polymerization
- R 2 is ⁇ CH 2 C3 ⁇ 4CH 2 NH 2; for serine oligopeptide, R 2 is -CH 2 OH; for glutamic acid oligopeptide, R 2 is -CH 2 CH 2 COOH.
- the amino acids in the oligopeptide may be the same (same polypeptide) or different (hetero-peptide).
- the amino acids used in the present invention include all natural amino acids and synthetic amino acids. Particularly preferred are glutamic acid, glycine, lysine, aspartic acid and serine.
- oligopeptide synthesis reference can be made to general synthetic methods.
- N-carboxyl acid anhydride (NCA) method Take the N-carboxyl acid anhydride (NCA) method as an example-
- This reaction has the following advantages: fast reaction speed and short synthesis cycle; after the synthesis is completed, the obtained amino-free peptide can be directly used in the second round of peptide synthesis without isolation.
- the side chain can be less protected.
- Glutamate oligopeptide compounds can be prepared by methods known in the art or can be obtained from commercial sources.
- the multi-branched branched polyethylene glycol-amino acid oligopeptide of the present invention is formed by reacting a multi-branched branched polyethylene glycol and an amino acid oligopeptide.
- the multi-branched branched polyethylene glycol end group it is necessary to activate the multi-branched branched polyethylene glycol end group to ensure that it can react with the amino or carboxyl group of the oligopeptide to combine the two.
- the following methods can be used to modify the functional groups of the end groups: a. Aminated, hydrophilic polymer after aminoation, the hydroxyl group is replaced by a more reactive amino group. It is particularly important that carboxylic acid group-containing molecules react to form a bond. b. Carboxylation. After carboxylation of a hydrophilic polymer, its reactivity can be improved, so that it can react with another molecule containing an amino group or a hydroxyl group to form a bond.
- multi-branch branched polyethylene glycol-amino acid oligopeptides can be combined with these drug molecules in the same way to replace biological organic molecules, and overcome the shortcomings of short biological half-life and short duration of drug effect in the body of drug molecules.
- the conjugate of the multi-branched branched polyethylene glycol-amino acid oligopeptide of the present invention and a drug molecule can be represented by the following formula:
- P is a multi-branch branched polyethylene glycol-amino acid oligopeptide
- ii is an integer from 1 to 30, which represents the number of drug molecules on the polyethylene glycol-amino acid oligopeptide;
- TA is a drug molecule
- the bond connecting the drug molecule TA may be an easily hydrolyzable bond (such as an ester bond) or a stable bond.
- Multi-branch branched polyethylene glycol-glutamic acid oligopeptides and drug molecules can be combined, for example, by forming an ester bond by reaction Together, the process can simply be as follows:
- the ester bond is an easily hydrolyzable bond that can be degraded in the organism to release the active ingredient.
- Other easily hydrolyzed bonds include: carbonate, carboxamide bonds, and the like.
- a suitable drug molecule can be used to constitute the drug part, which includes amino acids, proteins, enzymes, nucleosides, sugars, organic acids, glycosides, flavones, quinones, terpenes, phenylpropyl Phenols, steroids and their glycosides, alkaloids, etc.
- the drug molecule portion is preferably a pharmaceutically active ingredient isolated from a natural plant, such as toxin, glycyrrhetinic acid, boxwood, scutellarin, and scorolactone.
- the molecular part of the drug is particularly preferably a natural drug component for treating tumors, such as paclitaxel, camptothecin, etoposide, cantharidin, triptolide, and derivatives thereof.
- paclitaxel including irinotecan and topotecan
- paclitaxel derivatives including docetaxel and deacetyl taxol (Taxotere first, ta X otere).
- the conjugates of the present invention can be administered in the form of a pure compound or a suitable pharmaceutical composition, and can be performed using any acceptable method of administration or agents for similar uses.
- the method of administration adopted may be oral, intranasal, parenteral, topical, transdermal or rectal, and the form is solid, semi-solid, lyophilized powder or liquid pharmaceutical form, for example, tablets, Suppositories, pills, soft and hard gelatin capsules, powders, solutions, suspensions or aerosols, etc. are preferably used in unit dosage forms suitable for simple administration of precise doses.
- the composition may include a conventional pharmaceutical carrier or excipient and the conjugate of the present invention as an active ingredient (one or more), and may further include other agents, carriers, adjuvants, and the like.
- a pharmaceutically acceptable composition will contain from about 1 to about 99% by weight of a conjugate of the invention, and from 99 to 1% by weight of a suitable pharmaceutical excipient.
- the composition comprises from about 5 to 75% by weight of the conjugate of the invention, the balance being suitable pharmaceutical excipients.
- the pharmaceutical composition that can be administered in liquid form can be dissolved and dispersed in a carrier by dissolving or dispersing the conjugate of the present invention (about 0.5 to about 20%) and a selective pharmaceutical adjuvant. Examples are water, saline, aqueous dextrose, glycerol, ethanol, etc. to form a solution or suspension.
- the pharmaceutical composition of the present invention may also contain a small amount of auxiliary substances, such as wetting or emulsifying agents, PH buffering agents, antioxidants, etc., such as: citric acid, sorbitan monolaurate, triethanolamine Oleate, butylated hydroxytoluene, etc.
- auxiliary substances such as wetting or emulsifying agents, PH buffering agents, antioxidants, etc., such as: citric acid, sorbitan monolaurate, triethanolamine Oleate, butylated hydroxytoluene, etc.
- the composition used will contain a therapeutically effective amount of a conjugate of the present invention for the treatment of a corresponding disease.
- the present invention also provides a gel formed by a multi-branched polyethylene glycol-amino acid oligopeptide under appropriate conditions.
- the gel is multi-branch-branched polyethylene glycol-amino acid oligopeptide or its active derivative with other molecules And other small molecules).
- Gels can be formed by covalent or non-covalent bonding.
- a gel formed by covalent bonding can be characterized by:
- 1 is an integer from 2-20;
- LA polyethylene glycol-glutamic acid dipeptide
- glycine dipeptide Glu-Glu
- DMF dimethylformamide
- 3 g of the tetrabranched polyethylene glycol monosuccinimide carbonate prepared in Example 1 was added to the solution ( (Molecular weight is 10,000).
- the solution was stirred at room temperature for 6 hours, and the turbidity was removed by filtration. The residue was precipitated with 100 ml of isopropanol, filtered, and the product was dried under vacuum. The product can be purified by ion exchange chromatography. A tetrad-branched polyethylene glycol-glycine dipeptide (2a) was obtained. Yield: 2.5 g. HNMR (DMSO): 3.5 (br m, hydrogen in PEG), 4.54 (t, 2 hydrogen), 4.91 (s, 2 gas).
- DMSO dimethylformamide
- glycine dipeptide (Ghi-Glu) was dissolved in 20 ml of dimethylformamide (DMF), and 3 g of the trifurcation branched polyethylene glycol monosuccinimide carbonate (MOL 15000). The solution was stirred at room temperature for 6 hours, and the turbidity was removed by filtration. The residue was precipitated with 100 ml of isopropanol, filtered, and the product was dried under vacuum. The product can be purified by ion exchange chromatography. A trifurcation branched polyethylene glycol-glycine dipeptide (2b) was obtained. Yield: 2.5 g. HNMR (DMSO) : 3.5 (br m, hydrogen in PEG), 4.54 (t, 2 hydrogens), 4.91 (s, 2 hydrogens).
- camptothecin N-tert-butoxycarbonylglycine prepared from the previous step
- 10 ml of trifluoroacetic acid was added, and the mixture was stirred at room temperature for 5 hours.
- the solution was concentrated under reduced pressure, and 50 ml of ether was added.
- the precipitate was collected by filtration, and dried under vacuum to prepare a camptothecin derivative.
- a tetrabranched polyethylene glycol glutamate dipeptide (prepared from Example 1 with a molecular weight of 10,000) was dissolved in 10 ml of dichloroformamidine. Add 300 mg of bufalin, 32 mg of 4-dimethylaminopyridine (DMAP), and 200 mg of dicyclohexylcarbodiimide (DCC). The solution was stirred under nitrogen at room temperature overnight. The excess solvent was removed by rotary evaporation, and the residue was dissolved by adding 20 ml of 1,4-dioxane. The precipitate was removed by filtration, the solution was concentrated, the residue was added with 100 ml of isopropyl alcohol (IPA), filtered, and the product was dried under vacuum. The tetrabranched branched polyethylene glycol-glutamic acid dipeptide-Huabuxin ester (5) was obtained. Yield: 0.5 g. Melting point: 58—60 °.
- tetrabranched polyethylene glycol-lysine tetrapeptide (molecular weight 10000, prepared from Example 10), dissolved in 1 ml of a phosphate buffer solution (0.1M, pH 7.4), and added 1 ml of phosphate Buffer solution (0.1M, pH 7.4) containing 50 mg of polyglutamic acid (molecular weight 10000). The solution was gently shaken until a gel was formed.
- compositions This example illustrates the preparation of a representative parenteral pharmaceutical composition comprising a conjugate of the invention.
- Example 5 0.9% saline solution to 100 ml.
- the conjugate of Example 5 was dissolved in 0.9% saline solution to obtain 100 ml of a solution for intravenous injection, which was filtered through a 0.2 ⁇ m membrane filter material and packaged under sterile conditions.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200410048016.6 | 2004-06-11 | ||
CNB2004100480166A CN100475837C (zh) | 2004-06-11 | 2004-06-11 | 多叉分支的聚乙二醇-氨基酸寡肽及其活性衍生物和药物结合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005121181A1 true WO2005121181A1 (fr) | 2005-12-22 |
Family
ID=35503014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2005/000834 WO2005121181A1 (fr) | 2004-06-11 | 2005-06-10 | Polyethyleneglycol-oligopeptides de type branchement d'arbre multipoint et leurs derives actifs et composes |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN100475837C (zh) |
WO (1) | WO2005121181A1 (zh) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007133807A2 (en) * | 2006-05-15 | 2007-11-22 | Massachusetts Institute Of Technology | Polymers for functional particles |
EP1957089A2 (en) * | 2005-12-06 | 2008-08-20 | Tyco Healthcare Group, LP | Carbodiimide crosslinking of functionalized polethylene glycols |
ITRM20080551A1 (it) * | 2008-10-15 | 2010-04-16 | Univ Catania | Derivati anfifilici del poliossietilenglicole (peg), procedimento di preparazione e loro usi nella preparazione di sistemi farmaceutici. |
US8562998B2 (en) | 2008-10-12 | 2013-10-22 | President And Fellows Of Harvard College | Targeting of antigen presenting cells with immunonanotherapeutics |
US8637028B2 (en) | 2008-10-12 | 2014-01-28 | President And Fellows Of Harvard College | Adjuvant incorporation in immunonanotherapeutics |
US8906381B2 (en) | 2008-10-12 | 2014-12-09 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IGG humoral response without T-cell antigen |
US8932595B2 (en) | 2008-10-12 | 2015-01-13 | Massachusetts Institute Of Technology | Nicotine immunonanotherapeutics |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
US9333179B2 (en) | 2007-04-04 | 2016-05-10 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US9474717B2 (en) | 2007-10-12 | 2016-10-25 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
US9855338B2 (en) | 2005-12-05 | 2018-01-02 | Nitto Denko Corporation | Polyglutamate-amino acid conjugates and methods |
CN108264538A (zh) * | 2017-01-04 | 2018-07-10 | 辽宁药联制药有限公司 | 门冬氨酸缩合物的固相合成方法 |
CN112251484A (zh) * | 2020-10-26 | 2021-01-22 | 江南大学 | 一种脂肪酶催化制备甘氨酸寡肽-聚乙二醇共聚物的方法 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101168594B (zh) * | 2006-10-24 | 2011-07-27 | 北京键凯科技有限公司 | 寡肽为骨架的聚乙二醇活性衍生物、其制备方法及与药物分子的结合物 |
CN101724144A (zh) | 2008-11-03 | 2010-06-09 | 北京键凯科技有限公司 | 新型的多臂聚乙二醇及其制备方法和应用 |
CN102108119A (zh) * | 2009-12-25 | 2011-06-29 | 天津键凯科技有限公司 | 多臂聚乙二醇衍生物及其与药物的结合物和凝胶 |
CN102266566B (zh) * | 2010-06-03 | 2013-06-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种磁性复合物及其制备方法和用途 |
JP6488129B2 (ja) * | 2011-10-03 | 2019-03-20 | ナンヤン テクノロジカル ユニヴァーシティー | 優れた広域スペクトル抗微生物活性および高い選択性を有するカチオン性ペプチド多糖類 |
CN103083680B (zh) * | 2011-11-07 | 2014-12-24 | 北京键凯科技有限公司 | 聚乙二醇-氨基酸寡肽-依诺替康药物结合物及其药物组合物 |
WO2014114262A1 (zh) * | 2013-01-28 | 2014-07-31 | 天津键凯科技有限公司 | 水溶性聚合物-氨基酸寡肽-药物结合物及其制备方法和用途 |
US9700633B2 (en) | 2013-01-28 | 2017-07-11 | Jenkem Technology Co., Ltd., Tianjin Branch | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof |
WO2015081821A1 (zh) * | 2013-12-02 | 2015-06-11 | 北京键凯科技有限公司 | 聚乙二醇-多爪寡肽键合的雷帕霉素衍生物 |
CN105017522A (zh) * | 2015-07-20 | 2015-11-04 | 湖南华腾制药有限公司 | 聚乙二醇修饰的非天然氨基酸的制备方法 |
CN106924754B (zh) * | 2015-12-30 | 2021-11-09 | 北京大学 | 聚氨基酸偶联物 |
CN107469089B (zh) * | 2016-06-07 | 2022-01-07 | 北京键凯科技股份有限公司 | 一种peg连接子及配基药物偶联物 |
CN108659227B (zh) | 2017-03-30 | 2020-11-06 | 北京键凯科技股份有限公司 | 一种y型分支的亲水性聚合物羧酸衍生物的制备方法 |
WO2018177055A1 (zh) * | 2017-03-30 | 2018-10-04 | 北京键凯科技股份有限公司 | 一种y型分支的亲水性聚合物羧酸衍生物的制备方法 |
CN108003342A (zh) * | 2018-02-02 | 2018-05-08 | 中国科学院长春应用化学研究所 | 聚氨基酸、其制备方法和载药凝胶 |
US20210147624A1 (en) * | 2018-03-29 | 2021-05-20 | Nof Corporation | Degradable polyethylene glycol derivative |
CN109897179B (zh) * | 2019-04-02 | 2021-08-17 | 中国科学院长春应用化学研究所 | 一种多臂聚乙二醇-聚(l-谷氨酸酯)嵌段共聚物及其制备方法和应用 |
EP4036149A4 (en) * | 2019-09-26 | 2023-10-25 | NOF Corporation | HETEROBIFUNCTIONAL MONODISPERSPERED POLYETHYLENE GLYCOL WITH PEPTIDE LINKER |
CN115975182A (zh) * | 2023-01-10 | 2023-04-18 | 深圳市乐土生物医药有限公司 | 一种氨基酸共聚物及其应用 |
CN116178733B (zh) * | 2023-03-03 | 2023-08-01 | 浙江博美生物技术有限公司 | 一种基于三官能团氨基酸的支化单分散peg衍生物、制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1384512A (zh) * | 2001-04-16 | 2002-12-11 | 希普列公司 | 电容器用的电介质层板及其制造方法 |
WO2003074586A1 (fr) * | 2002-03-05 | 2003-09-12 | Beijing Jiankai Technology Co., Ltd | Compose d'oligopeptide de polycarboxyle/de polymere hydrophile et medicaments, composition medicale renfermant le compose susmentionne et utilisation dudit compose dans des medicaments |
CN1461762A (zh) * | 2002-05-30 | 2003-12-17 | 中国科学院过程工程研究所 | 制备分枝型聚乙二醇的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1176137C (zh) * | 2002-01-15 | 2004-11-17 | 泛亚生物技术有限公司 | 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用 |
-
2004
- 2004-06-11 CN CNB2004100480166A patent/CN100475837C/zh active Active
-
2005
- 2005-06-10 WO PCT/CN2005/000834 patent/WO2005121181A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1384512A (zh) * | 2001-04-16 | 2002-12-11 | 希普列公司 | 电容器用的电介质层板及其制造方法 |
WO2003074586A1 (fr) * | 2002-03-05 | 2003-09-12 | Beijing Jiankai Technology Co., Ltd | Compose d'oligopeptide de polycarboxyle/de polymere hydrophile et medicaments, composition medicale renfermant le compose susmentionne et utilisation dudit compose dans des medicaments |
CN1461762A (zh) * | 2002-05-30 | 2003-12-17 | 中国科学院过程工程研究所 | 制备分枝型聚乙二醇的方法 |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
US9855338B2 (en) | 2005-12-05 | 2018-01-02 | Nitto Denko Corporation | Polyglutamate-amino acid conjugates and methods |
EP1957089A4 (en) * | 2005-12-06 | 2012-06-20 | Tyco Healthcare | CARBODIIMIDE CROSSLINKING OF FUNCTIONALIZED POLYETHYLENE GLYCOLS |
EP1957089A2 (en) * | 2005-12-06 | 2008-08-20 | Tyco Healthcare Group, LP | Carbodiimide crosslinking of functionalized polethylene glycols |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
US8367113B2 (en) | 2006-05-15 | 2013-02-05 | Massachusetts Institute Of Technology | Polymers for functional particles |
WO2007133807A2 (en) * | 2006-05-15 | 2007-11-22 | Massachusetts Institute Of Technology | Polymers for functional particles |
WO2007133807A3 (en) * | 2006-05-15 | 2008-12-04 | Massachusetts Inst Technology | Polymers for functional particles |
US9688812B2 (en) | 2006-05-15 | 2017-06-27 | Massachusetts Institute Of Technology | Polymers for functional particles |
US9080014B2 (en) | 2006-05-15 | 2015-07-14 | Massachusetts Institute Of Technology | Polymers for functional particles |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
US9333179B2 (en) | 2007-04-04 | 2016-05-10 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
US10736848B2 (en) | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9526702B2 (en) | 2007-10-12 | 2016-12-27 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9539210B2 (en) | 2007-10-12 | 2017-01-10 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US11547667B2 (en) | 2007-10-12 | 2023-01-10 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9474717B2 (en) | 2007-10-12 | 2016-10-25 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US8637028B2 (en) | 2008-10-12 | 2014-01-28 | President And Fellows Of Harvard College | Adjuvant incorporation in immunonanotherapeutics |
US9439859B2 (en) | 2008-10-12 | 2016-09-13 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunoanotherapeutics |
US9308280B2 (en) | 2008-10-12 | 2016-04-12 | Massachusetts Institute Of Technology | Targeting of antigen presenting cells with immunonanotherapeutics |
US9233072B2 (en) | 2008-10-12 | 2016-01-12 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8932595B2 (en) | 2008-10-12 | 2015-01-13 | Massachusetts Institute Of Technology | Nicotine immunonanotherapeutics |
US8906381B2 (en) | 2008-10-12 | 2014-12-09 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IGG humoral response without T-cell antigen |
US8562998B2 (en) | 2008-10-12 | 2013-10-22 | President And Fellows Of Harvard College | Targeting of antigen presenting cells with immunonanotherapeutics |
ITRM20080551A1 (it) * | 2008-10-15 | 2010-04-16 | Univ Catania | Derivati anfifilici del poliossietilenglicole (peg), procedimento di preparazione e loro usi nella preparazione di sistemi farmaceutici. |
CN108264538A (zh) * | 2017-01-04 | 2018-07-10 | 辽宁药联制药有限公司 | 门冬氨酸缩合物的固相合成方法 |
CN108264538B (zh) * | 2017-01-04 | 2023-08-29 | 辽宁药联制药有限公司 | 门冬氨酸缩合物的固相合成方法 |
CN112251484A (zh) * | 2020-10-26 | 2021-01-22 | 江南大学 | 一种脂肪酶催化制备甘氨酸寡肽-聚乙二醇共聚物的方法 |
CN112251484B (zh) * | 2020-10-26 | 2022-05-24 | 江南大学 | 一种脂肪酶催化制备甘氨酸寡肽-聚乙二醇共聚物的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100475837C (zh) | 2009-04-08 |
CN1706865A (zh) | 2005-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005121181A1 (fr) | Polyethyleneglycol-oligopeptides de type branchement d'arbre multipoint et leurs derives actifs et composes | |
JP4365221B2 (ja) | 親水性ポリマー−マルチカルボキシルオリゴペプチドと薬剤分子との結合生成物、医薬組成物およびその薬学上の使用 | |
JP4272537B2 (ja) | Y型分鎖親水性ポリマー誘導体、それらの調製方法、前記誘導体および薬剤分子の結合生成物、ならびに前記結合生成物を含む医薬組成物 | |
WO2005092898A1 (fr) | Conjugue d'extraits de tripterydium a polymere hydrophile et leurs compositions pharmaceutiques | |
WO2010060260A1 (zh) | 新型的多臂聚乙二醇及其制备方法和应用 | |
WO2011075953A1 (zh) | 多臂聚乙二醇衍生物及其与药物的结合物和凝胶 | |
ES2659778T3 (es) | Conjugado farmacéutico de polietilenglicol-oligopéptido de aminoácidos-irinotecán y composición farmacéutica del mismo | |
CN101448875A (zh) | 鬼臼毒素类的高分子量结合体 | |
JP2019510126A (ja) | マルチアームポリエチレングリコール及びその活性誘導体 | |
CN112843242B (zh) | 一种聚乙二醇偶联药物、其制备方法及应用 | |
CN108026271A (zh) | 6配位铂络合物的高分子偶联物 | |
JP5105166B2 (ja) | ポリエーテルの製造方法 | |
WO2003080593A1 (fr) | Conjugues hydrophiles de polymeres-flavonoides et compositions pharmaceutiques les contenant | |
WO2005044837A1 (fr) | Conjugues d'extraits de buxus et de polymere hydrophile et compositions pharmaceutiques correspondantes | |
CN110418653B (zh) | 一种果胶-阿霉素轭合物及其制备方法和用途 | |
CN110152013B (zh) | 一种果胶-阿霉素轭合物及其制备方法和用途 | |
WO2003095522A1 (fr) | Polymeres hydrophiles de ciblage se liant a l'interferon et composite medical les comprenant | |
JP5189243B2 (ja) | 薬物複合体および薬物送達用担体 | |
CN1756758A (zh) | 新型的斑蝥胺和去甲斑蝥胺衍生物及其在医药中的应用 | |
CN1556801A (zh) | 亲水性聚合物-黄酮结合物以及包含该结合物的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |